Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Tuberculosis Blood Test Recommended For Key Groups

By LabMedica International staff writers
Posted on 12 Apr 2011
A blood test for latent tuberculosis infection (LTBI) should be the primary test in certain suspect groups suggests a recent official recommendation. More...


The innovative blood test, called the interferon-gamma release assay (IGRAs), is now thought to be more reliable than the Mantoux Tuberculin Sensitivity technique especially where the individual has already been vaccinated or was skin test positive.

In recognition of the mounting clinical evidence in favor of IGRA technology, the UK National Institute for Health and Clinical Excellence (NICE; London, UK), recommend directly using an IGRA blood test in a number of specified instances. These include: in an outbreak situation when large numbers of individuals may need to be screened; recent arrivals from high incidence countries who are from 16 to 34 years old; the immunocompromised and some people with human immunodeficiency virus (HIV); new health service employees who have recently arrived from high incidence countries or who have had contact with patients in a setting where tuberculosis is highly prevalent.

These interventions are designed to identify subjects with LTBI so that they can be treated before they convert to active disease. This proactive approach will help to reduce the rates of active TB disease in the UK, which have been rising over the past decade. The IGRA blood test is produced by Oxford Immunotec (Marlborough, MA, USA) and sold under the name T-SPOT.TB test.

Peter Wrighton-Smith, PhD, CEO of Oxford Immunotec, said, "I very much welcome the new guidelines from NICE which recognize the superior accuracy and convenience of IGRA testing in many populations. I am optimistic that the adoption of these guidelines will help to reverse the steadily increasing rates of TB seen in the UK over the past decade." The T-SPOT.TB test is approved for sale in Europe, USA, Canada, and over 40 other countries worldwide and is designed to replace the 115-year-old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB.

Related Links:
UK National Institute for Health and Clinical Excellence
Oxford Immunotec



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.